[Skip to Content]
[Skip to Content Landing]
Article
June 1986

Cefotaxime vs Nafcillin and Tobramycin for the Treatment of Serious Infection: Comparative Cost-effectiveness

Arch Intern Med. 1986;146(6):1153-1157. doi:10.1001/archinte.1986.00360180159024
Abstract

• To evaluate the cost-effectiveness of cefotaxime sodium at a dosage of 12 g/day vs nafcillin sodium and tobramycin sulfate for the treatment of serious infection, the hospital and physician charges of patients enrolled in a prospective, randomized, clinical trial were analyzed. For 187 patients receiving therapy empirically, mean hospital charges for the interval in which the trial antibiotics were used were $3,550±$1,740 for cefotaxime and $3,160±$1,990 for nafcillin and tobramycin. After adjusting for cost-generating factors, charges for cefotaxime were greater than for nafcillin and tobramycin, but the difference was not significant. For 107 patients with clinically or bacteriologically documented infection, mean charges were $3,980±$1,800 for cefotaxime and $4,170±$1,780 for nafcillin and tobramycin. Adjusted charges did not differ. Incremental charges for cefotaxime per additional response were $1,630 in all patients and -$820 in patients with clinically or bacteriologically documented infections.

(Arch Intern Med 1986;146:1153-1157)

References
1.
Carmine AA, Brogden RN, Heel RC, et al:  Cefotaxime: A review of its antibacterial activity, pharmacological properties and therapeutic use.  Drugs 1983;25:223-289.Crossref
2.
Cello JP, Grendell JH, Crass RA, et al:  Endoscopic sclerotherapy versus portacaval shunt in patients with severe cirrhosis and variceal hemorrhage.  N Engl J Med 1985;311:1589-1593.Crossref
3.
Reeder GS, Krishan I, Nobrega FT, et al:  Is percutaneous coronary angioplasty less expensive than bypass surgery?  N Engl J Med 1984;311: 1157-1162.Crossref
4.
Smith CR, Aminder R, Lipsky JJ, et al:  Cefotaxime versus nafcillin/ tobramycin for serious bacterial infections: A randomized, double-blind trial.  Ann Intern Med 1984;101:469-477.Crossref
5.
McCabe WR, Jackson GG:  Gram-negative bacteria: I. Etiology and ecology.  Arch Intern Med 1962;110:847-855.Crossref
6.
Meigs WB, Meigs RF:  Accounting: The Basis for Business Decisions ed 6. New York, McGraw-Hill International Book Co, 1984, pp 1043-1070.
7.
 SAS Users Guide: Statistics . Cary, NC, SAS Institute Inc, 1982.
8.
Finkler SA:  The distinction between costs and charges.  Ann Intern Med 1982;96:102-109.Crossref
9.
Smith CR, Lipsky JJ, Laskin OL, et al:  Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin.  N Engl J Med 1980;302:1106-1109.Crossref
10.
Smith CR, Lietman PS:  Comparative clinical trials of aminoglycosides , in Whelton A, Neu HC (eds):  The Aminoglycosides: Microbiology, Clinical Use and Toxicology . New York, Marcel Dekker Inc, 1982, pp 497-509.
11.
Moore RD, Smith CR, Lipsky JJ, et al:  Risk factors for nephrotoxicity in patients receiving aminoglycosides.  Ann Intern Med 1984; 100:352-357.Crossref
×